Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Banyan Group Inc

Neither a doctor nor a teaching hospital

Research payments

$54,542

49 payments

Through program year 2025, Banyan Group Inc is reported as receiving $54,542 in research payments, across 49 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $710 2
2024 Research $2,487 4
2023 Research $6,028 6
2022 Research $6,478 7
2021 Research $13,984 8
2020 Research $10,982 12
2019 Research $13,872 10

Breakdown

Who paid Research payments · program years 2019–2025
  1. Eli Lilly and Company $52,670 47 payments
  2. Pfizer Inc. $1,873 2 payments
Studies the money was for Research payments · program years 2019–2025
  1. Efficacy and Safety of Tirzepatide Once Weekly in Participants Without Type 2 Diabetes Who Have Obesity Or Are Overweight With Weight- Related Comorbidities: A Randomized, Double-Blind, Placebo-Controlled Trial (Surmount-1) $13,909 5 payments
  2. The Effect of Tirzepatide Versus Dulaglutide on Major Adverse Cardiovascular Events in Patients With Type 2 Diabetes (Surpass Cvot) $6,614 5 payments
  3. Assessment of Safety, Tolerability, and Efficacy of Ly3303560 in Early Symptomatic Alzheimer's Disease $4,469 2 payments
  4. Efficacy and Safety of Tirzepatide Once Weekly Versus Placebo After An Intensive Lifestyle Program in Participants Without Type 2 Diabetes Who Have Obesity Or Are Overweight With Weight-Related Comorbidities: A Randomized, Double Blind, Placebo-Controlled Trial (Surmount-3) $3,685 1 payment
  5. A Phase 3, Randomized, Open-Label Trial Comparing Efficacy and Safety of Tirzepatide Versus Semaglutide Once Weekly As Add-On Therapy to Metformin in Patients With Type 2 Diabetes $3,256 2 payments
  6. Efficacy and Safety of Tirzepatide Once Weekly in Participants Without Type 2 Diabetes Who Have Obesity Or Are Overweight With Weight- Related Comorbidities: A Randomized Double-Blind Placebo-Controlled Trial (Surmount-1) $2,163 1 payment
  7. A Randomized, Double Blind, Placebo Controlled, Parallel Group Phase 3 Study of Baricitinib in Patients With Covid 19 Infection $1,981 1 payment
  8. Phase 3B4 Randomized Safety Endpoint Study of 2 Doses of Tofacitinib in Comparison to A Tumor Necrosis Factor TNF Inhibitor in Subjects With Rheumatoid Arthritis $1,873 2 payments
  9. A Phase 3, Multicenter, Randomized, Double-Blind, Parallel, Placebo-Controlled Induction Study of Mirikizumab in Conventional-Failed and Biologic-Failed Patients With Moderately to Severely Active Ulcerative Colitis (Lucent 1) $1,851 1 payment
  10. Anti-Amyloid Treatment in Asymptomatic Alzheimers Disease -A4 Study $1,427 4 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record